In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

Shio-Shin Jean,1,2 Min-Chi Lu,3 Zhi-Yuan Shi,4 Shu-Hui Tseng,5 Ting-Shu Wu,6 Po-Liang Lu,7 Pei-Lan Shao,8 Wen-Chien Ko,9 Fu-Der Wang,10,11 Po-Ren Hsueh12,13 1Department of Emergency Medicine and Emergency and Critical Care Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; 2Depa...

Full description

Bibliographic Details
Main Authors: Jean SS, Lu MC, Shi ZY, Tseng SH, Wu TS, Lu PL, Shao PL, Ko WC, Wang FD, Hsueh PR
Format: Article
Language:English
Published: Dove Medical Press 2018-10-01
Series:Infection and Drug Resistance
Subjects:
Online Access:https://www.dovepress.com/in-vitro-activity-of-ceftazidimendashavibactam-ceftolozanendashtazobac-peer-reviewed-article-IDR
id doaj-c10a4401cfed4be18e2b445ba2ba7151
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Jean SS
Lu MC
Shi ZY
Tseng SH
Wu TS
Lu PL
Shao PL
Ko WC
Wang FD
Hsueh PR
spellingShingle Jean SS
Lu MC
Shi ZY
Tseng SH
Wu TS
Lu PL
Shao PL
Ko WC
Wang FD
Hsueh PR
In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
Infection and Drug Resistance
Enterobacteriaceae
Neisseria gonorrhoeae
extended-spectrum β-lactamases
carbapenemase
ceftolozane-tazobactam
ceftazidime-avibactam
author_facet Jean SS
Lu MC
Shi ZY
Tseng SH
Wu TS
Lu PL
Shao PL
Ko WC
Wang FD
Hsueh PR
author_sort Jean SS
title In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
title_short In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
title_full In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
title_fullStr In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
title_full_unstemmed In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
title_sort in vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important gram-negative bacilli: results from the 2017 surveillance of multicenter antimicrobial resistance in taiwan (smart)
publisher Dove Medical Press
series Infection and Drug Resistance
issn 1178-6973
publishDate 2018-10-01
description Shio-Shin Jean,1,2 Min-Chi Lu,3 Zhi-Yuan Shi,4 Shu-Hui Tseng,5 Ting-Shu Wu,6 Po-Liang Lu,7 Pei-Lan Shao,8 Wen-Chien Ko,9 Fu-Der Wang,10,11 Po-Ren Hsueh12,13 1Department of Emergency Medicine and Emergency and Critical Care Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; 2Department of Emergency, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 3Department of Microbiology and Immunology, School of Medicine, China Medical University, Taichung, Taiwan; 4Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 5Center for Disease Control and Prevention, Ministry of Health and Welfare, Taiwan; 6Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan; 7Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 8Department of Pediatrics, Hsin-Chu Branch, National Taiwan University Hospital, Hsin-Chu, Taiwan; 9Department of Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan; 10Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 11School of Medicine, National Yang-Ming University, Taipei, Taiwan; 12Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; 13Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan Objectives: We investigated the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria (GNB) from 16 major teaching hospitals in Taiwan in 2017. Materials and methods: Escherichia coli (n=686) and Klebsiella pneumoniae bloodstream isolates (n=673), non-typhoid Salmonella (NTS; n=221) from various sources, Shigella species (n=21) from fecal samples, and Neisseria gonorrhoeae (n=129) from the genitourinary tract were collected. Antibiotic minimum inhibitory concentrations (MICs) were determined using the broth microdilution method. Alleles encoding K. pneumoniae carbapenemases (KPCs), New Delhi metallo-β-lactamases (NDMs), Verona integron-encoded metallo-β-lactamase, imipenemase, OXA-48-like, and mcr-1-5 genes were detected by molecular methods in Enterobacteriaceae isolates. Results: Five (0.7%) E. coli isolates harbored mcr-1 alleles. Twenty-four (3.6%), seven (1.0%), four (0.6%), and one (0.15%) K. pneumoniae isolates contained bla KPC, bla OXA-48-like, mcr-1, and bla NDM, respectively. Three (1.4%) NTS and no Shigella isolates harbored mcr-1 genes. Seventy-one (10.5%) K. pneumoniae isolates displayed non-susceptibility (NS) to carbapenem agent(s). Phenotypically extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae isolates showed significantly higher rates of ertapenem, tigecycline, and ceftolozane–tazobactam (CLZ–TAZ) NS (40.2%, 16.3%, and 71%–80%, respectively) than E. coli isolates exhibiting ESBL phenotypes (5.4%, 0.7%, and 18%–28%, respectively). All phenotypically ESBL-producing E. coli isolates were ceftazidime–avibactam (CAZ–AVB) susceptible. Two (8.3%) KPC-producing K. pneumoniae isolates showed CAZ–AVB NS. Hospital-acquired K. pneumoniae isolates were significantly less susceptible to ertapenem and CLZ–TAZ than hospital-acquired E. coli isolates. Conclusion: Third-generation cephalosporins remain the optimal choice for treating NTS, Shigella, and gonococcal infections in Taiwan. Hospital-acquired and phenotypically ESBL-producing K. pneumoniae are a heavy resistance burden in Taiwan. Keywords: Enterobacteriaceae, Neisseria gonorrhoeae, extended-spectrum β-lactamases, carbapenemase, ceftolozane–tazobactam, ceftazidime–avibactam
topic Enterobacteriaceae
Neisseria gonorrhoeae
extended-spectrum β-lactamases
carbapenemase
ceftolozane-tazobactam
ceftazidime-avibactam
url https://www.dovepress.com/in-vitro-activity-of-ceftazidimendashavibactam-ceftolozanendashtazobac-peer-reviewed-article-IDR
work_keys_str_mv AT jeanss invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart
AT lumc invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart
AT shizy invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart
AT tsengsh invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart
AT wuts invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart
AT lupl invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart
AT shaopl invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart
AT kowc invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart
AT wangfd invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart
AT hsuehpr invitroactivityofceftazidimendashavibactamceftolozanendashtazobactamandothercomparableagentsagainstclinicallyimportantgramnegativebacilliresultsfromthe2017surveillanceofmulticenterantimicrobialresistanceintaiwansmart
_version_ 1725764720263168000
spelling doaj-c10a4401cfed4be18e2b445ba2ba71512020-11-24T22:23:21ZengDove Medical PressInfection and Drug Resistance1178-69732018-10-01Volume 111983199241828In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)Jean SSLu MCShi ZYTseng SHWu TSLu PLShao PLKo WCWang FDHsueh PRShio-Shin Jean,1,2 Min-Chi Lu,3 Zhi-Yuan Shi,4 Shu-Hui Tseng,5 Ting-Shu Wu,6 Po-Liang Lu,7 Pei-Lan Shao,8 Wen-Chien Ko,9 Fu-Der Wang,10,11 Po-Ren Hsueh12,13 1Department of Emergency Medicine and Emergency and Critical Care Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; 2Department of Emergency, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 3Department of Microbiology and Immunology, School of Medicine, China Medical University, Taichung, Taiwan; 4Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 5Center for Disease Control and Prevention, Ministry of Health and Welfare, Taiwan; 6Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan; 7Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 8Department of Pediatrics, Hsin-Chu Branch, National Taiwan University Hospital, Hsin-Chu, Taiwan; 9Department of Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan; 10Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 11School of Medicine, National Yang-Ming University, Taipei, Taiwan; 12Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; 13Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan Objectives: We investigated the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria (GNB) from 16 major teaching hospitals in Taiwan in 2017. Materials and methods: Escherichia coli (n=686) and Klebsiella pneumoniae bloodstream isolates (n=673), non-typhoid Salmonella (NTS; n=221) from various sources, Shigella species (n=21) from fecal samples, and Neisseria gonorrhoeae (n=129) from the genitourinary tract were collected. Antibiotic minimum inhibitory concentrations (MICs) were determined using the broth microdilution method. Alleles encoding K. pneumoniae carbapenemases (KPCs), New Delhi metallo-β-lactamases (NDMs), Verona integron-encoded metallo-β-lactamase, imipenemase, OXA-48-like, and mcr-1-5 genes were detected by molecular methods in Enterobacteriaceae isolates. Results: Five (0.7%) E. coli isolates harbored mcr-1 alleles. Twenty-four (3.6%), seven (1.0%), four (0.6%), and one (0.15%) K. pneumoniae isolates contained bla KPC, bla OXA-48-like, mcr-1, and bla NDM, respectively. Three (1.4%) NTS and no Shigella isolates harbored mcr-1 genes. Seventy-one (10.5%) K. pneumoniae isolates displayed non-susceptibility (NS) to carbapenem agent(s). Phenotypically extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae isolates showed significantly higher rates of ertapenem, tigecycline, and ceftolozane–tazobactam (CLZ–TAZ) NS (40.2%, 16.3%, and 71%–80%, respectively) than E. coli isolates exhibiting ESBL phenotypes (5.4%, 0.7%, and 18%–28%, respectively). All phenotypically ESBL-producing E. coli isolates were ceftazidime–avibactam (CAZ–AVB) susceptible. Two (8.3%) KPC-producing K. pneumoniae isolates showed CAZ–AVB NS. Hospital-acquired K. pneumoniae isolates were significantly less susceptible to ertapenem and CLZ–TAZ than hospital-acquired E. coli isolates. Conclusion: Third-generation cephalosporins remain the optimal choice for treating NTS, Shigella, and gonococcal infections in Taiwan. Hospital-acquired and phenotypically ESBL-producing K. pneumoniae are a heavy resistance burden in Taiwan. Keywords: Enterobacteriaceae, Neisseria gonorrhoeae, extended-spectrum β-lactamases, carbapenemase, ceftolozane–tazobactam, ceftazidime–avibactamhttps://www.dovepress.com/in-vitro-activity-of-ceftazidimendashavibactam-ceftolozanendashtazobac-peer-reviewed-article-IDREnterobacteriaceaeNeisseria gonorrhoeaeextended-spectrum β-lactamasescarbapenemaseceftolozane-tazobactamceftazidime-avibactam